On June 1, Medicare officials announced plans to cover new FDA-approved drugs that may slow the progression of Alzheimer’s disease. The Centers for Medicare and Medicaid Services would also require patients using the drugs to register for the purpose of gathering information on treatment results.
Tag Archives: drugs
N.C. journalist goes to Europe for lessons about opioid crisis
Last year, Taylor Knopf, a health care journalist at North Carolina Health News, spent more than a week out of a vacation to report on how France and Switzerland have been able to do what the health care system in the United States has so far failed to do: stem the tide of opioid-related deaths.
Knopf earned first place in AHCJ’s Awards for Excellence in Health Care Journalism Public Health (small) category for her six-part NCHN series, “Lessons from Abroad.” Continue reading
Tip sheet on covering alcohol highlights do’s, don’ts and story ideas
Every day, stories about the U.S. opioid epidemic appear in daily newsfeeds, and rightly so: they are responsible for two out of every three drug overdoses in the country.
But there’s another drug not included in the usual drug overdose stats which kills almost twice as many people a year as opioids — alcohol. And yet, a casual perusal of the daily headlines usually turns up as many fun or fluff stories about alcohol as ones that suggest the risks and harms of drinking. Continue reading
FTC charges in Shkreli case shed light on need for new generic drug development
The Federal Trade Commission and State of New York late last month filed a lawsuit against Martin Shkreli, charging that Shkreli and Vyera Pharmaceuticals raised the price of the life-saving drug Daraprim by more than 4,000% and worked to corner the market for such drugs.
“The joint action accused Shkreli and Vyera Pharmaceuticals, formerly known as Turing Pharmaceuticals, of scheming to ‘illegally’ prevent would-be generic competitors from selling a version of Daraprim,” as Stat’s Ed Silverman reported on Jan. 27. After acquiring the drug in 2015, Shkreli, dubbed the “Pharma Bro,” and Turing raised the list price of the medication from $17.50 per tablet to $750, he added. Continue reading
Webcast to feature author of book on rampant fraud in the generic drug industry
Investigative journalist Katherine Eban will discuss her new book documenting rampant fraud in the generic drug industry during an AHCJ webcast on Wednesday, June 19.
In her book, “Bottle of Lies: The Inside Story of the Generic Drug Boom,” Eban reveals how generic drug makers not only help ensure that some of the worst quality drugs enter the least regulated markets but also take extreme measures to avoid regulatory scrutiny. Harper Collins/Ecco’s Hardcover division published the book on May 14. Continue reading